PubMed · 1968 · 95 citations · 0 references
MedicineBiochemistryPharmacologyCancer PharmacologyCellular MetabolismChemotherapyDna ChemistryNucleotide Metabolism5-Fluorouracil Therapy5-Fluorouracil TreatmentFluorinated Nucleic AcidsNucleoside AnalogsPyrimidine AnalogsPyrimidine AnaloguesPyrimidine ChemistryPyrimidine Synthesis Inhibitors
Summary The effects of a number of pyrimidine nucleoside analogs on the growth of HeLa, Novikoff hepatoma, and L 5178 leukemia cells in culture have been determined. Information on the biochemical mechanisms of action has been obtained by experiments on the prevention of the inhibition by normal metabolites and by reversal from inhibition by delayed addition of the normal metabolites. In HeLa cells the appropriate normal metabolites prevented the inhibition produced by 5-fluorouracil, 5-fluoro-2′-deoxyuridine (FUDR), 5-fluorouridine, 2′,3′-dehydro-5-fluoro-2′-deoxyuridine, 5-iodo-2′-deoxyuridine, 5-trifluoromethyl-2′-deoxyuridine, and arabinofuranosylcytosine. Delayed addition of the normal metabolites reversed the inhibition produced by the above compounds with the exception of 5-trifluoromethyl-2′-deoxyuridine and 5-iodo-2′-deoxyuridine, which were not reversed by thymidine, and the inhibition by 5-fluorouridine, which was not reversed by uridine, suggesting that the irreversible toxicity was the consequence of incorporation of these analogs into nucleic acids. Cell lines of the Novikoff hepatoma and L 5178Y leukemias were studied that were resistant to FUDR as a result of a loss of thymidine kinase. These cells were effectively inhibited by 2′,3-dehydro-5-fluoro-2′-deoxyuridine, a new analog that is not phosphorylated by thymidine kinase. With the exception of arabinofuranosylcytosine, all the compounds exerted widely differing toxicities to the various cell lines.